Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.68 |
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
| ▸ | PNP | P00491 | 1/20 | 0.61 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
| ▸ | KRAS | P01116 | 3/20 | 0.56 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16113852 | 1.00 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL16114085 | 1.00 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL8064383 | 1.00 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL13833305 | 1.00 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL16114035 | 1.00 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| Phosphoric Acid SCHEMBL1971262 | 0.96 | NT5E (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| Guanosine SCHEMBL24049416 | 0.91 | HPGD (0.76) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| Guanosine SCHEMBL24049608 | 0.91 | HPGD (0.76) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| Guanosine SCHEMBL7062800 | 0.91 | HPGD (0.76) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| Guanosine SCHEMBL24049417 | 0.91 | HPGD (0.76) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| US-10723753-B2 | Ras inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723753-B2 | Ras inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| EP-2707483-B1 | METHODS AND MATERIALS FOR NUCLEIC ACID MANIPULATION | RWTH AACHEN UNIV (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-9688715-B2 | Synthetic pGpG analogs, methods of preparation and methods of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688715-B2 | Synthetic pGpG analogs, methods of preparation and methods of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2970360-A1 | RAS INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150175649-A1 | SYNTHETIC pGpG ANALOGS, METHODS OF PREPARATION AND METHODS OF USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-06-25 | — | — | US | disclosed |
| US-20150175649-A1 | SYNTHETIC pGpG ANALOGS, METHODS OF PREPARATION AND METHODS OF USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-06-25 | — | — | US | disclosed |
| WO-2014160200-A9 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| WO-2014160200-A9 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| WO-2014160200-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160200-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20120295311-A1 | Methods and Materials for Nucleic Acid Manipulation | BASF SE (DE) | 2012-11-22 | — | — | US | disclosed |
| EP-1015629-A1 | BIOCONJUGATION OF OLIGONUCLEOTIDES | Proligo L.L.C. (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998030720-A1 | BIOCONJUGATION OF OLIGONUCLEOTIDES | PROLIGO LLC (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175649-A1 | SYNTHETIC pGpG ANALOGS, METHODS OF PREPARATION AND METHODS OF USE | MRPL21, PGLS, CFTR | HINT1 1449/4885NT5E 505/4885GSK3A 4501/4885 |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, RASGRP1 | HINT1 3139/4885NT5E 2879/4885GSK3A 3434/4885 |
| US-10723753-B2 | Ras inhibitors and uses thereof | KRAS, NRAS, RASGRP1 | HINT1 3139/4885NT5E 2879/4885GSK3A 3434/4885 |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | ASGR1, HAVCR2, SIGLEC7 | HINT1 846/4885NT5E 123/4885GSK3A 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.